12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Although KRAS mutation has a predictive role in stage IV colorectal cancer (CRC) patients treated with anti-EGFR therapy, there have been controversies in the prognostic impact of KRAS mutation in stage II or III disease. The purpose of this study was to assess the prognostic impact of KRAS and BRAF mutation in patients treated with adjuvant 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX).

          Related collections

          Author and article information

          Journal
          Ann Surg Oncol
          Annals of surgical oncology
          Springer Science and Business Media LLC
          1534-4681
          1068-9265
          Jan 2015
          : 22
          : 1
          Affiliations
          [1 ] Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
          Article
          10.1245/s10434-014-3826-z
          24889488
          68ccad58-ccec-49c2-8f62-e1dfd08691bf
          History

          Comments

          Comment on this article